ML Pharma
Timeline
9 events since 2023Filings
Financial
Establishments
2023202420252026
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed NBBabbreviated format · 28 days before the deadline
2025
Weakest financial year net €13,891 ▼79.2% The net result drops to €13,891, the lowest from 2023 to 2025.
Registered in the Peppol Directory Reachable for e-invoices through 0208:0795627454
Annual accounts 2024 filed PDFfull format · 23 days before the deadline
2024
Highest result from 2023 to 2025 net €66,859 ▲96.1% The operating result of €108,420 and the net result of €66,859 are both a record.
Equity above €100,000 equity €109,260 ▲153% With a profit in every financial year since 2023, equity grows to €109,260.
Annual accounts 2023 filed PDFfull format · 22 days before the deadline
2023
IncorporationFounding capital of €10,000, 100 shares · Founder: IGASS Amale (comparante fondatrice) · Appointment: IGASS Amale (director) · published on 04-01-20235 points ▸
- Founder, IGASS Amale (comparante fondatrice)
- Founding capital, €10,000, 100 shares
- Registered office clause, avenue Houba de Strooper 773, 1020 Bruxelles
- Board rule, 1
- Director appointment, IGASS Amale (director (not named in the articles))
- The deed holds 3 more points.
First establishment Houba de Strooperlaan 773, Brussels
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank